Ranolazine-d8
Based on 1 Customer Validation
Ranolazine-d8 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor. Antianginal agent.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.83%
- CAS. Nr.: 1092804-88-0
- Formel: C24H25D8N3O4
- Molecular Weight:435.59
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Calcium Channel Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS. Nr. 1092804-88-0
-
Unlabeled Cas 95635-55-5
-
Appearance Solid
-
Molecular Weight 435.59
-
Formel C24H25D8N3O4
-
Color White to off-white
-
SMILES
O(CC(CN1C(C(N(CC(NC2=C(C)C=CC=C2C)=O)C(C1([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])O)C3=C(OC)C=CC=C3
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (229.57 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73. [Content Brief]
[3]. Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. [Content Brief]
[4]. Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2957 mL | 11.4787 mL | 22.9574 mL | 57.3934 mL |
| 5 mM | 0.4591 mL | 2.2957 mL | 4.5915 mL | 11.4787 mL | |
| 10 mM | 0.2296 mL | 1.1479 mL | 2.2957 mL | 5.7393 mL | |
| 15 mM | 0.1530 mL | 0.7652 mL | 1.5305 mL | 3.8262 mL | |
| 20 mM | 0.1148 mL | 0.5739 mL | 1.1479 mL | 2.8697 mL | |
| 25 mM | 0.0918 mL | 0.4591 mL | 0.9183 mL | 2.2957 mL | |
| 30 mM | 0.0765 mL | 0.3826 mL | 0.7652 mL | 1.9131 mL | |
| 40 mM | 0.0574 mL | 0.2870 mL | 0.5739 mL | 1.4348 mL | |
| 50 mM | 0.0459 mL | 0.2296 mL | 0.4591 mL | 1.1479 mL | |
| 60 mM | 0.0383 mL | 0.1913 mL | 0.3826 mL | 0.9566 mL | |
| 80 mM | 0.0287 mL | 0.1435 mL | 0.2870 mL | 0.7174 mL | |
| 100 mM | 0.0230 mL | 0.1148 mL | 0.2296 mL | 0.5739 mL |
Ranolazine-d8 Related Classifications
HY-B0280S1 Related Classifications
Powered by Bioz